Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Alector Inc (NASDAQ:ALEC) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue ...

Alector (NASDAQ:ALEC – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on ...

Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$0.54 (-10.2% Y/Y) and the consensus Revenue Estimate ...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical ...

Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...

Alector, Inc. has a 52-week low of $1.55 and a 52-week high of $7.58. The stock has a market cap of $163.54 million, a price-to-earnings ratio of -0.98 and a beta of 0.61. Analyst Upgrades and ...